用户48783635432019-04-09 14:29
【汇众医疗】Navidea宣布重启NAV3-31的2b期临床试验,此后股价上升13%
$Navidea生物制药(NAVB)$ Navidea根据FDA的反馈,宣布重启对NAV3-31的2b期临床试验计划,评估成像剂Tc99m tilmanocept在类风湿性关节炎患者中的应用。此举促进该公司股价上升了13%。 查看全文网页链接查看全文
艾萨克的猫2018-10-23 23:00
$Navidea Biopharmaceuticals, Inc. (NAVB)$ Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced today the company will pr...查看全文
$Navidea生物制药(NAVB)$ 8-A12G Registration of securities [Section 12(g)] Accession Number: 0001437749-23-017735 Act: 34 Size: 62 KB 网页链接
$Navidea生物制药(NAVB)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001104659-23-072256 Act: 34 Size: 61 KB 网页链接
$Navidea生物制药(NAVB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-23-017587 Size: 11 KB 网页链接
$Navidea生物制药(NAVB)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001415889-23-009574 Size: 4 KB 网页链接
$Navidea生物制药(NAVB)$ 3 Initial statement of beneficial ownership of securities Accession Number: 0001415889-23-009497 Size: 7 KB 网页链接
$Navidea生物制药(NAVB)$ 8-K Current report, items 1.01, 3.01, 3.02, 5.02, 8.01, and 9.01 Accession Number: 0001437749-23-016520 Act: 34 Size: 283 KB 网页链接
$Navidea生物制药(NAVB)$ SD Specialized disclosure report Accession Number: 0001437749-23-016311 Act: 34 Size: 16 KB 网页链接
$Navidea生物制药(NAVB)$ 8-K Current report, items 1.01, 3.02, 5.03, 8.01, and 9.01 Accession Number: 0001437749-23-015848 Act: 34 Size: 380 KB 网页链接
$Navidea生物制药(NAVB)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001437749-23-013972 Act: 34 Size: 5 MB 网页链接
$Navidea生物制药(NAVB)$ 424B5 Prospectus [Rule 424(b)(5)] Accession Number: 0001437749-23-011527 Act: 33 Size: 520 KB 网页链接